KRAS and cancer: In these 79 patients with CCNE1 amplified cancer, concurrent genetic aberrations were found in approximately 94% of these patients all patients (n = 74; 93%), and three or more concomitant genetic aberrations were found in 39 patients (49%): TP53 (n = 52; 66%), PIK3CA (n = 19; 24%), KRAS (n = 14; 18%), AKT1/2 (n = 9; 11%), BRAF (n = 9; 11%), PTEN (n = 9; 11%), MYC (n = 8; 10%), MET (n = 6; 8%), BRCA1 (n = 5; 6%), and EGFR (n = 5; 6%).